Press Release
G2GBio has the best subject matter experts in the field of the injectable drug development.
|
G2GBIO teams up with Celltrion to develop ultra-concentrated antibody SC formulations
2026.08.07
HIT 1398
|
|---|
|
G2GBIO teams up with Celltrion to develop ultra-concentrated antibody SC formulations
- Application scope broadened to encompass bispecific antibodies, ADCs, and recombinant proteins - Celltrion antibodies integrated into novel drug delivery platform ‘InnoBioLAMP’ [by Ji, Yong Jun] G2GBIO is partnering with Celltrion to develop an ultra-high-concentration antibody formulation platform for subcutaneous (SC) administration. G2GBIO announced on July 30 that it signed a memorandum of understanding (MOU) with Celltrion for ‘technology cooperation on ultra-high-concentration antibody SC formulation platform,’ including a material transfer agreement (MTA). The agreement aims to explore the feasibility of developing ultra-high-concentration subcutaneous formulations of antibody therapeutics using G2GBIO’s novel drug delivery platform, ‘InnoBioLAMP.’ Through the collaboration, G2GBIO plans to expand its business scope into antibodies and other biopharmaceuticals, building on its existing microparticle-based long-acting injectable platform, ‘InnoLAMP.’ The two companies will assess whether Celltrion’s antibodies can be formulated as ultra-high-concentration SC products using InnoBioLAMP, while exploring future joint research and commercialization strategies. G2GBIO expects the platform to support a broad range of biologics beyond conventional antibodies to include bispecific antibodies, antibody-drug conjugates (ADCs), and recombinant proteins. "In the global antibody drug market, securing subcutaneous formulations that improve patient convenience is becoming increasingly important. We look forward to leveraging G2GBIO's technology to evaluate the potential of reformulating our proprietary drug candidates and expanding the scope of our collaboration," a Celltrion official commented. "Through this collaboration, we will validate InnoBioLAMP’s applicability to antibody therapeutics and assess its competitive potential. We will advance development efforts with the aim of pursuing joint research and ultimately achieving commercialization in the future," said Lee Hee-yong, CEO of G2GBIO. |